Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Macaulay, V M; Middleton, M R; Protheroe, A S; Tolcher, A; Dieras, V; Sessa, C; Bahleda, R; Blay, J-Y; LoRusso, P; Mery-Mignard, D; Soria, J-C

Macaulay, V M; Middleton, M R; Protheroe, A S; Tolcher, A; Dieras, V; Sessa, C; Bahleda, R; Blay, J-Y; LoRusso, P; Mery-Mignard, D; Soria, J-C.

Affiliation

Macaulay VM; Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LE, UK. valentine.macaulay@oncology.ox.ac.uk

Ann Oncol ; 24(3): 784-91, 2013 Mar.

Article in En | MEDLINE | ID: mdl-23104723

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leiomyosarcoma/drug therapy; Melanoma/drug therapy; Skin Neoplasms/drug therapy; Soft Tissue Neoplasms/drug therapy; Adult; Aged; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Diarrhea/chemically induced; Docetaxel; Doxorubicin/administration & dosage; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines/administration & dosage; Receptor, IGF Type 1/immunology; Taxoids/administration & dosage; Treatment Outcome; Gemcitabine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 / 3_ND Database: MEDLINE Main subject: Skin Neoplasms / Soft Tissue Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Leiomyosarcoma / Melanoma Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google